Fast response in facial vitiligo monitored by non-invasive imaging during topical ruxolitinib treatment
Dear Editor, Vitiligo is a chronic autoimmune disorder affecting 0.5-1% of the population, characterized by progressive melanocyte loss and depigmented macules. Non-segmental vitiligo (NSV) is the most common subtype, typically involving the face and acral areas, with relevant psychosocial impact. Conventional therapies frequently provide delayed or incomplete responses. Recently, topical Janus kinase (JAK) inhibitors, such as ruxolitinib 1.5% cream, have shown promise in promoting repigmentation. [...].
Authors
- Giovanni Pellacani (ORCID: https://orcid.org/0000-0002-7222-2951)
- Annunziata Dattola (ORCID: https://orcid.org/0000-0001-9504-5882)
- Francesca Paola Sasso (ORCID: https://orcid.org/0000-0002-6072-6300)
- Maria Elisabetta Greco (ORCID: https://orcid.org/0009-0008-5067-8190)
- Alberto di Caro (ORCID: https://orcid.org/0009-0009-6110-4309)
- Steven Paul Nisticò (ORCID: https://orcid.org/0000-0002-3828-0883)
- Francesca Feresin (ORCID: https://orcid.org/0009-0001-0662-5592)
Institutions
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Dermatology Reports
- Published
- 2026-10-27
- DOI
- https://doi.org/10.4081/dr.2026.10964
- Primary Topic
- melanin and skin pigmentation
- Type
- article
- Field-Weighted Citation Impact
- 0.00